May 31, 2016
Article
Features
Patients with melanoma who were treated with a combination of Opdivo and Yervoy showed no significant changes in their quality of life when compared to those who were treated with either agent alone.
May 27, 2016
Article
Features
Why is the development of vitiligo a predictor of good response in patients taking immunotherapy for melanoma, and what can scientists learn from this?
May 27, 2016
Article
Features
Triple wild-type melanoma may not respond to approved targeted drugs, but immunotherapy can be an excellent option.
May 26, 2016
Article
Features
In the fast-moving world of melanoma treatment, new therapeutic options for patients with metastatic disease are emerging faster than oncology researchers can establish guidelines for their optimal clinical use. That is raising questions about which should be the firstline choice in metastatic melanoma — targeted drugs or immunotherapy — and how these drugs should be sequenced.
May 26, 2016
Article
Features
In clinical trials, melanoma remains a ripe discovery ground for the application and combination of immunotherapies and targeted drugs.